Koers OKYO Pharma Limited London S.E.
Aandelen
OKYO
GG00BMFG5F62
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 48,86 mln. 45,7 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -11 mln. -10,29 mln. | Nettowinst (verlies) 2025 * | -15 mln. -14,03 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-3,68
x | K/w-verhouding 2025 * |
-3,87
x | Werknemers | 8 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 42,63% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Gary Jacob
CEO | Chief Executive Officer | 77 | 07-01-21 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | 01-08-20 |
William Clementi
COO | Chief Operating Officer | - | 01-09-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 10-06-20 |
Willy Simon
BRD | Director/Board Member | 72 | 01-06-15 |
Gabriele Cerrone
CHM | Chairman | 52 | 07-01-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-4,66% | 87,53 mld. | |
+1,32% | 40,42 mld. | |
-19,27% | 29,48 mld. | |
+57,86% | 25,43 mld. | |
-17,69% | 11,49 mld. | |
-43,00% | 11,3 mld. | |
-9,14% | 11,1 mld. | |
+5,24% | 8,75 mld. | |
-8,42% | 7,99 mld. |